Approved comparison material connected to this topic.
3 total recordsSource comparisons are presented without a generated winner.
Teichman et al. 2006 49 participants 28 days 100 mcg/kg Injection-site erythema (18%) None reported Resting HR/BP only None Largest trial; short observation window limits chronic safety signal detection Ionesc…
The addition of Drug Affinity Complex (DAC) to CJC-1295 extends the peptide's half-life from 30 minutes to approximately 6–8 days by binding non-covalently to serum albumin. This pharmacokinetic modification f…
The following table compares CJC-1295 no DAC safety profile against longer-acting GHRH analogs and combination secretagogue protocols. CJC-1295 no DAC ~30 minutes 2-3x daily 20-35% 15-25% Moderate (daily antig…